REGN7257

REGN7257 is an experimental, fully human monoclonal antibody developed by Regeneron Pharmaceuticals that targets the interleukin-2 receptor subunit gamma (IL2RG), also known as the common gamma chain. By inhibiting IL2RG, REGN7257 blocks signaling from multiple cytokines in the common gamma chain family (including IL2, IL4, IL7, IL9, IL15, and IL21), which are key drivers of T cell-mediated immune responses. The drug is being developed primarily for severe aplastic anemia (SAA) that is refractory to or has relapsed after standard immunosuppressive therapy. Preclinical studies have also explored its potential in preventing graft rejection and treating other T cell-mediated diseases by suppressing pathogenic T-cell responses.

Other names

anti-interleukin-2 receptor subunit gamma monoclonal antibodyanti-interleukin2 receptor subunit gamma monoclonal antibodyanti-interleukin 2 receptor subunit gamma monoclonal antibody